Antimicrobial Agents and Chemotherapy, March 2001, p. 952-955, Vol. 45, No. 3
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.3.952-955.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
L.R.M.A., Université Paris VI, 75270 Paris Cedex 06,1 and Service de Bactériologie, Hôpital Saint-Joseph, 75674 Paris Cedex 14,2 France
Received 27 July 2000/Returned for modification 22 September 2000/Accepted 19 December 2000
For an in vitro mutant of Streptococcus pneumoniae selected on moxifloxacin four- to eightfold-increased MICs of new fluoroquinolones, only a twofold-increased MIC of ciprofloxacin, and a twofold-decreased MIC of novobiocin were observed. This phenotype was conferred by two mutations: Ser81Phe in GyrA and a novel undescribed His103Tyr mutation in ParE, outside the quinolone resistance-determining region, in the putative ATP-binding site of topoisomerase IV.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |